Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2010-04-21
2011-11-15
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S234100, C514S001100, C514S912000
Reexamination Certificate
active
08057808
ABSTRACT:
Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6620415 (2003-09-01), Donovan
patent: 6689816 (2004-02-01), Fogel
patent: 6762687 (2004-07-01), Perlman
patent: 6921538 (2005-07-01), Donovan
patent: 6955813 (2005-10-01), Brooks et al.
patent: 7390496 (2008-06-01), Ackerman
patent: 7393537 (2008-07-01), Ackerman
patent: 7393538 (2008-07-01), Ackerman
patent: 7396535 (2008-07-01), Ackerman
patent: 7422753 (2008-09-01), Ackerman
patent: 2004/0157926 (2004-08-01), Heresco-Levy
patent: 2006/0286127 (2006-12-01), Van Schaack
Kwak, Carolyn H., et al.,Botulinum Toxin in the Treatment of Tics, Arch Neurol., vol. 57, Aug. 2000, pp. 1190-1193.
Aoki, K.R. et al., Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions;European Journal Neurology; 2001; 8 (Suppl 5):pp. 21-29.
Aoki, K.R.; Physiology and Pharmacology of Therapeutic Botulinum Neurotoxins; In: Kreyden OP, ed.Hyperhidrosis and Botulinum Toxin in Dermatology; Current Problems in Dermatology: Basel, Karger; 2002; 30: pp. 107-116.
Attah Johnson et al. Int. J. Dermatol. 34: 244-248, 1995.
Bigalke, Hans et al., Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture;Brain Res; 1985; 360: pp. 381-324.
Bigalke, H. et al., Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord;Naunyn Schmiedebergs Arch Pharmacol; 1981; 316; pp. 244-251.
Binz, Thomas et al., The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins;J Biochem; (Tokyo) Jun. 5, 1990; 265(16); pp. 9153-9158.
Boyd, R.S. et al., The insulin secreting B-cell line, HIT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A;Mov. Disorders; May 1995; 10(3); 376.
Brem, Henry et al., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas;The Lancet;vol. 345; Apr. 22, 1995; pp. 1008-1012.
Brin, Mitchell F. et al., Botulinum Toxin Type A: Pharmacology; In: Mayer Nathaniel H, ed.Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin; 2002; pp. 110-124.
Carl Swartling, Botulinum Toxin in the Treatment of Focal Hyperhidrosis and Dyshidrotic Hand Dermatitis, 2002, Uppsala Universitet, DAI-C 63/04, p. 756 (Abstract), pp. 1-2.
Carl Swartling, Botulinum Toxin in the Treatment of Focal Hyperhidrosis and Dyshidrotic Hand Dermatitis, Comprehensive Summaries of Uppsala Dissertations 1164, 2002, pp. 1-67.
Carl Swartling et al., Treatment of Dyshidrotic Hand Dermatitis with Intradermal Botulinum Toxin, J. Am. Acad. Dermatol, Nov. 2002, vol. 47, No. 5, pp. 667-671.
Cermak T. Wien, Klin. Wochenschr, 92: 641-650, 1980, abstract.
Chappell, Phillip et al., Future Therapies of Tourette Syndrome;Neurol Clin; 1997; vol. 15, No. 2, May; pp. 429-450.
Cui, M. et al., Mechanisms of the Antinociceptive Effect of Subcutanous Botox®: Inhibition of Peripheral and Central Nociceptive Processing;Naunyn Schmiedebergs Arch Pharmacol; 2002; 365 (Suppl 2) R17; Abstract.
Dabrowski, E. et al., Botulinum Toxin as a Novel Treatment for Self Mutilation in Lesch-Nyhan Syndrome;Ann Neurol; 2002; 52(3): S157; Abstract.
DoctorNDTV Newsletter, Dec. 16, 2008.
Ferrari, David M. et al., The protein disulphide-isomerase family: unravelling a string of folds;Biochem J; 1999 (339) pp. 1-10.
Fung, Lawrence K. et al., Pharmacokinetics of Interstitial Delivery of Carmustine, 4-Hydroperoxycyclophosphamide, and Paclitaxel from a Biodegradable Polymer implant in the Monkey Brain;Cancer Research; 58, Feb. 15, 1998; pp. 672-684.
Greenberg S1. Psychosomatics 2: 109-111, 1961.
Habermann, E., I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord;Naunyn Schmiedeberg's Arch. Pharmacol; 1974; (281); pp. 47-56.
Habermann, E , Inhibition by tetanus and botulinum A toxin of the release of {3H}noradrenaline and {3H} GABA from rat brain homogenate;Experientia; Mar. 15, 1988; 44(3) pp. 224-226.
Habermann, E. et al., Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain;J Neurochem; vol. 51, No. 2 1988; pp. 522-527.
Jankovic, Joseph; Botulinum Toxin in the Treatment of Dystonic Tics;Movment Disorders; vol. 9, No. 3, 1994; pp. 347-349.
Jankovic, Joseph; Botulinum Toxin in the Treatment of Tics Associated with Tourette's Syndrome;Neurology; Apr. 1993; 43(4 Suppl 2); A310; Abstract.
Krauss, Joachim K. et al., Severe Motor Tics Causing Cervical Myelopathy in Tourette's Syndrome;Movement Disorders; vol. 11, No. 5, 1996; pp. 563-565.
Kudelko, K.M. et al., Successful treatment of recalcitrant restless legs syndrome with botulinum toxin A;Movment Disorders; 2002; 17 (Suppl 5); S242 ABS p. 779.
Marjama-Lyons, Jill et al., Tremor-Predominant Parkinson's Disease;Drugs&Aging; Apr. 16, 2000 (4) pp. 273-278.
Marc Heckmann, Botulinum Toxin Type A Injection in the Treatment of Lichen Simplex: An Open Pilot Study, J. Am. Acad. Dermatol., Apr. 2002, vol. 46, No. 4, pp. 617-619.
MMWR 49: 1115-1116, 2000, abstract.
Naumann, Markus et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions;European Journal of Neurology; 1999, vol. 6 (suppl 4) pp. S111-S115.
Niphon Poungvarin et al., Hemifacial Spasm Treated with Botulinum Toxin Injection: A Ten-Year Experience at Siriraj Hospital, Sir. Hosp. Gaze, Jan. 2001, vol. 53, No. 1, pp. 1-7.
Pearce, Bruce et al., Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine;Toxicon; 1997; 35 (9); pp. 1373-1412.
Ragona, Rosario M. et al., Management of Parotid Sialocele With Botulinum Toxin;Laryngoscope; 109; Aug. 1999 (8); pp. 1344-1346.
Rechenberger I, MMW Munch Med Wochenschr, 123: 1005-1006, 1981.
Sanchez-Prieto, Jose et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes;Eur J Biochem; Jun. 1987; 165 (3); pp. 675-681.
Schantz, Edward J. et al., Properties and Use of Boulinum Toxin and Other Microbial Neurotoxins in Medicine;Microbiol Review; Mar. 1992; 56 (1); pp. 80-99.
Singh, Bal Ram; Critical Aspects of Bacterial Protein Toxins;Natural Toxins II; Edited by B. R. Singh et al., Plenum Press, New Yrok, 1996; Chapter 4, pp. 63-84.
Sloop, Richard R. et al., Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use;Neurology; Jan. 1997; 48 (1); pp. 249-253.
Wiegand, H. et al., I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after intramuscular Injection;Naunyn Schmiedebergs Arch Pharmacol; 1976; 292; pp. 161-165.
Zigmond, et al.,Fundamental Neuroscience; 1999 by Academic Press, San Diego, CA; pp. 963-964.
Pranzatelli, Michael R.,Antidyskinetic Drug Therapy for Pediatric Movement Disorders, Journal of Child Neurology, vol. 11, No. 5, Sep. 1996, pp. 355-369.
Pry
Allergen, Inc.
Condino Debra
Devi S.
Gibson Hal
LandOfFree
Use of a botulinum neurotoxin to alleviate various disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a botulinum neurotoxin to alleviate various disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a botulinum neurotoxin to alleviate various disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297093